Chronic Lymphocytic Leukemia
We recommend
OHD 2024: What’s New in Data and Experiences from Real Practice with Venetoclax Regimens?
How to utilize venetoclax regimens most effectively for treating chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) in real practice was the topic of a satellite symposium organized by AbbVie during this year’s XXXVIth Olomouc Hematology Days. Three hemato-oncologists shared their experiences with venetoclax treatment, moderated by Prof. MUDr. Tomáš Papajík, CSc., from the Department of Hemato-Oncology, Faculty of Medicine, Palacky University and University Hospital Olomouc.
Benefits of Time-Limited CLL Therapy
The advent of new targeted molecules has significantly influenced the possibilities of therapy for…
Selecting from the Red Book CHS: What's New in This Year's Recommendations for the Diagnosis and Treatment of CLL?
Chronic lymphocytic leukemia (CLL) is the most common lymphoid malignancy in adults in Europe and…
Articles on this topic
Educational Brochure for Patients with CLL
Thanks to the expansion of modern therapies for chronic lymphocytic leukemia, many patients now...
Venetostart – The First Comprehensive Mobile Application with Practical Information for Venetoclax Treatment
Abbvie has developed the comprehensive mobile application Venetostart with practical…
Current NCCN Recommendations for Classification and Risk Symptoms in SLL/CLL
The new recommendations from the National Comprehensive Cancer Network (NCCN) regarding…
Incidence of Secondary Malignancies in CLL Patients on FCR Regimen in Central Europe
Chronic lymphocytic leukemia (CLL) represents the most common type of leukemia in Western…
Current NCCN Recommendations for CLL/SLL Diagnosis – Version 1.2023
In August 2022, the latest guidelines from the National Comprehensive Cancer Network (NCCN)…
Current Treatment Options for Refractory/Relapsed CLL
How have treatment protocols for chronic lymphocytic leukemia changed in recent years? A…
Sequential administration of immunochemotherapy and venetoclax after failure of BCR inhibitor treatment – interactive video case study
The treatment of chronic lymphocytic leukemia (CLL) is evolving. What was impossible years ago…
What can we base the decision on for the choice of initial treatment modality for CLL?
We now have a range of highly effective treatment options for patients with chronic…
Venetoclax Treatment Strategies in Patients with CLL
One of the new targeted preparations in the treatment of chronic lymphocytic leukemia (CLL) is…
Brief from ASH 2021: News and Advances in CLL Treatment
The summary from the first day of the 63rd American Society of Hematology (ASH) Congress in…
Subscribe
Most read on this topic
Journal on this topic
Related topic
Most read on this topic
- Chronic lymphocytic leukaemia – contemporary application of modern prognostic and predictive markers in diagnostics
- Venetoclax Treatment Strategies in Patients with CLL
- Current NCCN Recommendations for CLL/SLL Diagnosis – Version 1.2023
- Evolution of chronic lymphocytic leukemia treatment over the past 25 years
- Current Treatment Options for Refractory/Relapsed CLL
- Role of Chemoimmunotherapy in the Era of Rapid Development of CLL Treatment Strategies and Emergence of New Drugs
Journal on this topic
Related topic